In addition, the most important prognostic indicators for PanNETs are tumor grade and stage, while other prognostic indicators are also age, gender (with men having a slightly worse prognosis), the presence of symptoms at diagnosis, the presence of metastasis, surgical removal, chemotherapy, hormone therapy, radiation therapy, and certain molecular markers such as mutations in the KRAS and DAXX/ATRX genes [86,92,93,94]. This evidence concerns the gene KRAS and neoplasm.